Compare Goodyear Tire & Rubber Co (GT) vs Novo Nordisk A/S (NVO) Price & Performance

Goodyear Tire & Rubber (GT) trades at $4.69, up 0.64% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported a Q2 2026 loss of $0.61 per share, beating estimates but reflecting ongoing volume pressures. Revenue has declined from $20.8B in 2022 to $18.3B in 2025, with a net income margin of -14.37% in the latest period. Despite a low P/E of 4.69 and P/B of 0.48, negative ROE and ROA highlight profitability challenges. Recent news highlights a restructuring plan targeting margin improvement and debt reduction.

The outlook is mixed, with a consensus price target of $8.00 suggesting significant upside if restructuring succeeds. However, risks include persistent volume declines, high debt levels, and execution uncertainty. Analyst sentiment is cautious with 34.62% buy ratings, 50% hold, and 15.38% sell. Investors should weigh the deep value metrics against fundamental headwinds in the competitive tire industry.

Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.

The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.